140 related articles for article (PubMed ID: 25202433)
1. Ideal number of target lesions per organ to measure in metastatic colorectal cancer.
Kim HS; Kim JH
Oncol Lett; 2014 Oct; 8(4):1896-1900. PubMed ID: 25202433
[TBL] [Abstract][Full Text] [Related]
2. The assessment of tumor response by measuring the single largest lesion per organ in metastatic tumors: a pooled analysis of previously reported data.
Jang HJ; Cho JW; Park B; Choi HC; Kim HS; Kim JH
J Cancer; 2015; 6(2):169-76. PubMed ID: 25561982
[TBL] [Abstract][Full Text] [Related]
3. Tumor response assessment by measuring the single largest lesion per organ in patients with advanced non-small cell lung cancer.
Kim HS; Kim JH; Yang I
Lung Cancer; 2014 Sep; 85(3):385-9. PubMed ID: 25074845
[TBL] [Abstract][Full Text] [Related]
4. Single-lesion measurement per organ for assessing tumor response in advanced gastric cancer.
Kim HS; Kim JW; Kim JH; Choi DR; Han AR; Kim MJ; Kim BC; Zang DY
Oncology; 2015; 88(2):69-75. PubMed ID: 25277674
[TBL] [Abstract][Full Text] [Related]
5. Tumor response assessment by the single-lesion measurement per organ in small cell lung cancer.
Jung SG; Kim JH; Kim HS; Kim KJ; Yang I
Chin J Cancer Res; 2016 Apr; 28(2):161-7. PubMed ID: 27199513
[TBL] [Abstract][Full Text] [Related]
6. Comparison of RECIST 1.0 and RECIST 1.1 on computed tomography in patients with metastatic colorectal cancer.
Jang HJ; Kim BC; Kim HS; Kim JH; Song HH; Kim JB; Park JJ; Yoon SN; Woo JY; Zang DY
Oncology; 2014; 86(2):117-21. PubMed ID: 24480800
[TBL] [Abstract][Full Text] [Related]
7. Tumor response evaluation criteria for HCC (hepatocellular carcinoma) treated using TACE (transcatheter arterial chemoembolization): RECIST (response evaluation criteria in solid tumors) version 1.1 and mRECIST (modified RECIST): JIVROSG-0602.
Sato Y; Watanabe H; Sone M; Onaya H; Sakamoto N; Osuga K; Takahashi M; Arai Y;
Ups J Med Sci; 2013 Mar; 118(1):16-22. PubMed ID: 23167460
[TBL] [Abstract][Full Text] [Related]
8. Assessment of chemotherapy response in colorectal liver metastases in patients undergoing hepatic resection and the correlation to pathologic residual viable tumor.
Egger ME; Cannon RM; Metzger TL; Nowacki M; Kelly L; Tatum C; Scoggins CR; Callender GG; McMasters KM; Martin RC
J Am Coll Surg; 2013 Apr; 216(4):845-56; discussion 856-7. PubMed ID: 23415549
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the RECIST 1.0 and RECIST 1.1 in Non-Small Cell Lung Cancer Treated with Cytotoxic Chemotherapy.
Choi HC; Kim JH; Kim HS; Jung SG; Hwang SM; Ju SB; Yang I
J Cancer; 2015; 6(7):652-7. PubMed ID: 26078796
[TBL] [Abstract][Full Text] [Related]
10. Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma.
Edeline J; Boucher E; Rolland Y; Vauléon E; Pracht M; Perrin C; Le Roux C; Raoul JL
Cancer; 2012 Jan; 118(1):147-56. PubMed ID: 21713764
[TBL] [Abstract][Full Text] [Related]
11. New Response Evaluation Criteria in Solid Tumors (RECIST) guidelines for advanced non-small cell lung cancer: comparison with original RECIST and impact on assessment of tumor response to targeted therapy.
Nishino M; Jackman DM; Hatabu H; Yeap BY; Cioffredi LA; Yap JT; Jänne PA; Johnson BE; Van den Abbeele AD
AJR Am J Roentgenol; 2010 Sep; 195(3):W221-8. PubMed ID: 20729419
[TBL] [Abstract][Full Text] [Related]
12. EASL and mRECIST responses are independent predictors of survival in hepatocellular carcinoma patients treated with cryoablation.
Li H; Guo Z; Si T; Wang H
Eur J Gastroenterol Hepatol; 2013 May; 25(5):620-7. PubMed ID: 23325276
[TBL] [Abstract][Full Text] [Related]
13. CT of colon cancer metastases to the liver using modified RECIST criteria: determining the ideal number of target lesions to measure.
Zacharia TT; Saini S; Halpern EF; Sumner JE
AJR Am J Roentgenol; 2006 Apr; 186(4):1067-70. PubMed ID: 16554580
[TBL] [Abstract][Full Text] [Related]
14. Modified response evaluation criteria in solid tumors is superior to response evaluation criteria in solid tumors for assessment of responses to sorafenib in patients with advanced hepatocellular carcinoma.
Takada J; Hidaka H; Nakazawa T; Kondo M; Numata K; Tanaka K; Matsunaga K; Okuse C; Kobayashi S; Morimoto M; Ohkawa S; Koizumi W
BMC Res Notes; 2015 Oct; 8():609. PubMed ID: 26502722
[TBL] [Abstract][Full Text] [Related]
15. Comparison of RECIST version 1.0 and 1.1 in assessment of tumor response by computed tomography in advanced gastric cancer.
Jang GS; Kim MJ; Ha HI; Kim JH; Kim HS; Ju SB; Zang DY
Chin J Cancer Res; 2013 Dec; 25(6):689-94. PubMed ID: 24385696
[TBL] [Abstract][Full Text] [Related]
16. CT imaging findings in patients with advanced hepatocellular carcinoma treated with sorafenib: Alternative response criteria (Choi, European Association for the Study of the Liver, and modified Response Evaluation Criteria in Solid Tumor (mRECIST)) versus RECIST 1.1.
Gavanier M; Ayav A; Sellal C; Orry X; Claudon M; Bronowicki JP; Laurent V
Eur J Radiol; 2016 Jan; 85(1):103-112. PubMed ID: 26724654
[TBL] [Abstract][Full Text] [Related]
17. Comparison of tumor response assessment methods in patients with metastatic colorectal cancer after locoregional therapy.
Akinwande O; Philips P; Scoggins CR; Kelly L; Tatum C; Hahl M; McMasters KM; Martin RC
J Surg Oncol; 2016 Mar; 113(4):443-8. PubMed ID: 27060707
[TBL] [Abstract][Full Text] [Related]
18. Comparison of WHO and RECIST criteria for response in metastatic colorectal carcinoma.
Choi JH; Ahn MJ; Rhim HC; Kim JW; Lee GH; Lee YY; Kim IS
Cancer Res Treat; 2005 Oct; 37(5):290-3. PubMed ID: 19956529
[TBL] [Abstract][Full Text] [Related]
19. Modified response evaluation criteria in solid tumors and European Association for The Study of the Liver criteria using delayed-phase imaging at an early time point predict survival in patients with unresectable intrahepatic cholangiocarcinoma following yttrium-90 radioembolization.
Camacho JC; Kokabi N; Xing M; Prajapati HJ; El-Rayes B; Kim HS
J Vasc Interv Radiol; 2014 Feb; 25(2):256-65. PubMed ID: 24461131
[TBL] [Abstract][Full Text] [Related]
20. The true role of mRECIST guideline: does it really estimate viable tumor or merely improve accuracy in hepatocellular carcinoma response evaluation?
Liu Q; Li A; Sun S; Luo R; Chen F
J BUON; 2014; 19(2):398-405. PubMed ID: 24965398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
